SCHEMBL8345781

SCHEMBL8345781

O=C(O)CN1CC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
CRBN Q96SW2 2/20 0.38
ACE P12821 4/20 0.38
KMT2A Q03164 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
EPHX2 P34913 1/20 0.35
DDB1 Q16531 1/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MMP13 P45452 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1371699 0.98 TSHR (0.38) TSHRCRBNACEKMT2ACYP2D6
SCHEMBL8900385 0.82 TSHR (0.36) TSHRCRBNACEKMT2ACYP2D6
SCHEMBL3419632 0.82 KMT2A (0.37) TSHRACEKMT2ACYP2D6CYP2C19
SCHEMBL29961455 0.81 TSHR (0.46) TSHRCRBNACEKMT2APOLB
SCHEMBL26901495 0.81 CRBN (0.41) CRBNACEKMT2APOLBEPHX2
SCHEMBL11737558 0.81 CRBN (0.37) CRBNACEKMT2AEPHX2DDB1
SCHEMBL5077783 0.79 KDM4E (0.44) TSHRCRBNKMT2APOLBEPHX2
SCHEMBL26649756 0.76 KDM4E (0.42) CRBNACEKMT2APOLBKDM4E
SCHEMBL5945932 0.76 PTGS1 (0.42) TSHRCRBNKMT2APOLBLMNA
SCHEMBL7525177 0.75 CRBN (0.35) CRBNACEEPHX2DDB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function Lee Moffitt Cancer Center and Research Institute, Inc. (US) 2026-03-03 US disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 US disclosed
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis IDORSIA PHARMACEUTICALS LTD (CH) 2025-07-01 US disclosed
CN-114585637-B MASP-inhibitory compounds and uses thereof 拜耳公司 2025-04-15 CN disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 EP disclosed
CN-119497712-A Indane derivatives as MALT1 inhibitors 希四克斯探索有限公司 2025-02-21 CN disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 US disclosed
CN-112236424-B Alkoxy-substituted pyridinyl derivatives 爱杜西亚药品有限公司 2024-03-15 CN disclosed
WO-2023218203-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-11-16 WO disclosed
CN-114585637-A MASP inhibiting compounds and uses thereof 拜耳公司 2022-06-03 CN disclosed
EP-3966226-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF Bayer Aktiengesellschaft (DE) 2022-03-16 EP disclosed
US-20210246116-A1 ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS IDORSIA PHARMACEUTICALS LTD (CH) 2021-08-12 US disclosed
US-20210246166-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2021-08-12 US disclosed
CN-112779303-A Method for synthesizing orotic acid by biological enzyme method 华东理工大学 2021-05-11 CN disclosed
EP-3802517-A1 ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS Idorsia Pharmaceuticals Ltd (CH) 2021-04-14 EP disclosed
CN-112236424-A Alkoxy-substituted pyridyl derivatives 爱杜西亚药品有限公司 2021-01-15 CN disclosed
WO-2020225095-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-11-12 WO disclosed
WO-2019234115-A1 ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS IDORSIA PHARMACEUTICALS LTD (CH) 2019-12-12 WO disclosed
US-5912261-A ANTIDIABETIC AGENTS NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1999-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 TSHR 3032/4885CRBN 3026/4885ACE 22/4885
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis LPAR1, LPAR3, LPAR2 TSHR 542/4885CRBN 4064/4885ACE 967/4885
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function CRBN, CD4, ICOS TSHR 1705/4885CRBN 1/4885ACE 3749/4885
US-20210246116-A1 ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS LPAR1, LPAR3, LPAR2 TSHR 542/4885CRBN 4064/4885ACE 967/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 TSHR 3032/4885CRBN 3026/4885ACE 22/4885
US-20210246166-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 TSHR 3032/4885CRBN 3026/4885ACE 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.